Remove Competition Remove Government Remove Patients Remove Prescription
article thumbnail

The debate on DTC marketing is going to heat up again

World of DTC Marketing

SUMMARY: DTC marketing is not the reason why prescription drugs cost so much. Here are some myths around DTC marketing: 1ne: DTC ads result in patients asking for prescriptions they don’t need. 2wo: DTC marketing is one of the reasons prescription drugs cost so much. DTC ads raise awareness around health conditions.

Marketing 285
article thumbnail

The Inflation Reduction Act Passed, Now What?

PM360

In April 2022, we released an article describing proposed policies from the federal government that could impact prescription drug pricing. Government negotiation of drug prices. Patient behavior on insulin: Part D plans will have limited opportunity to adjust strategy for 2023, given bids are locked in.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Two Key Questions About Payer Strategies in 2023

PM360

What other policy issues or potential changes by the government should companies be aware of? However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. price of its most prescribed insulin brand.

article thumbnail

Fentanyl: a horrifyingly disruptive drug

Pharmaceutical Technology

Theft, fraudulent prescriptions and unsanctioned distribution by patients and medical practitioners are the most common ways in which legal fentanyl products are illegally secured. Fentanyl was first synthesised in 1959 and introduced to markets in the 1960s as a pain relief drug. A dangerous future.

Safety 105
article thumbnail

Teva asks SCOTUS to overturn “skinny label” verdict on GSK drug

pharmaphorum

The case hinges around the concept of “ skinny labelling ” which was introduced to stop drugmakers extending the exclusivity period for their branded medicines – through a stream of new indications or patient populations – that can be protected with so-called “use” patents. The substance patent expired in 2007.

article thumbnail

What health plans should know about healthcare price transparency

Clarify Health

No surprise billing: A breakdown of the key requirements and deadlines in the No Surprises Act The No Surprises Act aims to protect patients from receiving “surprise” (or unexpected) medical bills from a healthcare provider or facility after inadvertently receiving care from an out-of-network provider.

article thumbnail

Your 2024 Legal Vision Board: Trends and Opportunities for Digital Health Innovators

Nixon Gwilt Law

Keep an eye out for more software applications that accurately collect and analyze patient physiologic data using a laptop or smartphone camera—bypassing the need for any hardware device. What started as a drug to help patients with Type 2 diabetes is now the preferred weight loss aid of many celebrities, influencers, and everyday people.